141 related articles for article (PubMed ID: 27262904)
1. A novel rare sugar inhibitor of murine herpes simplex keratitis.
Muniruzzaman S; McIntosh M; Hossain A; Izumori K; Bhattacharjee PS
J Pharmacol Sci; 2016 Jun; 131(2):126-30. PubMed ID: 27262904
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model.
Bhattacharjee PS; Neumann DM; Foster TP; Clement C; Singh G; Thompson HW; Kaufman HE; Hill JM
Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4263-8. PubMed ID: 18515564
[TBL] [Abstract][Full Text] [Related]
3. Topical antisense-oligonucleotides targeting IFN-gamma mRNA improve incidence and severity of herpetic stromal keratitis by cytokine specific and sequence unspecific effects.
Wasmuth S; Bauer D; Steuhl KP; Heiligenhaus A
Graefes Arch Clin Exp Ophthalmol; 2008 Mar; 246(3):443-51. PubMed ID: 18030487
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo effects of polyhexamethylene biguanide against herpes simplex virus infection.
Valluri S; Fleming TP; Laycock KA; Tarle IS; Goldberg MA; Garcia-Ferrer FJ; Essary LR; Pepose JS
Cornea; 1997 Sep; 16(5):556-9. PubMed ID: 9294689
[TBL] [Abstract][Full Text] [Related]
5. 6-Thioguanine Inhibits Herpes Simplex Virus 1 Infection of Eyes.
Chen D; Liu Y; Zhang F; You Q; Ma W; Wu J; Wu Z
Microbiol Spectr; 2021 Dec; 9(3):e0064621. PubMed ID: 34730435
[TBL] [Abstract][Full Text] [Related]
6. Prevention of herpes simplex virus induced stromal keratitis by a glycoprotein B-specific monoclonal antibody.
Krawczyk A; Dirks M; Kasper M; Buch A; Dittmer U; Giebel B; Wildschütz L; Busch M; Goergens A; Schneweis KE; Eis-Hübinger AM; Sodeik B; Heiligenhaus A; Roggendorf M; Bauer D
PLoS One; 2015; 10(1):e0116800. PubMed ID: 25587898
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of herpes virus helicase-primase inhibitor, ASP2151, for treating herpes simplex keratitis in mouse model.
Sasaki S; Miyazaki D; Haruki T; Yamamoto Y; Kandori M; Yakura K; Suzuki H; Inoue Y
Br J Ophthalmol; 2013 Apr; 97(4):498-503. PubMed ID: 23361434
[TBL] [Abstract][Full Text] [Related]
8. Effects of antiviral medications on herpetic epithelial keratitis in mice.
Komoto S; Higaki S; Fukuda M; Shimomura Y
Jpn J Ophthalmol; 2015 May; 59(3):194-200. PubMed ID: 25707352
[TBL] [Abstract][Full Text] [Related]
9. Topical treatment with nerve growth factor in an animal model of herpetic keratitis.
Lambiase A; Coassin M; Costa N; Lauretti P; Micera A; Ghinelli E; Aloe L; Rama P; Bonini S
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):121-7. PubMed ID: 17479276
[TBL] [Abstract][Full Text] [Related]
10. Tetrandrine potently inhibits herpes simplex virus type-1-induced keratitis in BALB/c mice.
Hu S; Dutt J; Zhao T; Foster CS
Ocul Immunol Inflamm; 1997 Sep; 5(3):173-80. PubMed ID: 9326762
[TBL] [Abstract][Full Text] [Related]
11. Treatment with meliacine, a plant derived antiviral, prevents the development of herpetic stromal keratitis in mice.
Alché LE; Berra A; Veloso MJ; Coto CE
J Med Virol; 2000 Aug; 61(4):474-80. PubMed ID: 10897066
[TBL] [Abstract][Full Text] [Related]
12. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
Romanowski EG; Bartels SP; Gordon YJ
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
[TBL] [Abstract][Full Text] [Related]
13. Effect of oral valaciclovir on herpetic keratitis.
Higaki S; Itahashi M; Deai T; Fukuda M; Shimomura Y
Cornea; 2006 Dec; 25(10 Suppl 1):S64-7. PubMed ID: 17001196
[TBL] [Abstract][Full Text] [Related]
14. Geldanamycin is effective in the treatment of herpes simplex virus epithelial keratitis in a rabbit model.
Wu X; Tao P; Nie H
Clin Exp Ophthalmol; 2011 Nov; 39(8):779-83. PubMed ID: 22050565
[TBL] [Abstract][Full Text] [Related]
15. Application of FGF-2 to modulate herpetic stromal keratitis.
Kim B; Lee S; Kaistha SD; Rouse BT
Curr Eye Res; 2006 Dec; 31(12):1021-8. PubMed ID: 17169840
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic action of meliacine, a plant-derived antiviral, on HSV-induced ocular disease in mice.
Pifarré MP; Berra A; Coto CE; Alché LE
Exp Eye Res; 2002 Sep; 75(3):327-34. PubMed ID: 12384095
[TBL] [Abstract][Full Text] [Related]
17. Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application.
Berdugo M; Larsen IV; Abadie C; Deloche C; Kowalczuk L; Touchard E; Dubielzig R; Brandt CR; Behar-Cohen F; Combette JM
Antimicrob Agents Chemother; 2012 Mar; 56(3):1390-402. PubMed ID: 22203590
[TBL] [Abstract][Full Text] [Related]
18. High-Risk Corneal Graft Rejection in the Setting of Previous Corneal Herpes Simplex Virus (HSV)-1 Infection.
Kuffova L; Knickelbein JE; Yu T; Medina C; Amescua G; Rowe AM; Hendricks RL; Forrester JV
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1578-87. PubMed ID: 27050878
[TBL] [Abstract][Full Text] [Related]
19. Antiviral Activity of Oridonin Against Herpes Simplex Virus Type 1.
Jiang K; Feng J; Qi X; Ran L; Xie L
Drug Des Devel Ther; 2022; 16():4311-4323. PubMed ID: 36573068
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a theta-defensin in a Murine model of herpes simplex virus type 1 keratitis.
Brandt CR; Akkarawongsa R; Altmann S; Jose G; Kolb AW; Waring AJ; Lehrer RI
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5118-24. PubMed ID: 17962464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
